Meth on the rise in New Jersey

In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...

read more

Binding Methamphetamine to Release People from Addiction

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders.  Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS.  IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866).  We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Meth on the rise in New Jersey

In August 2018, the DEA Intelligence Program, in conjunction with the NY/NJ High Intensity Drug Trafficking Area program and the NJ State Police Regional Operations Intelligence Center’s Drug Monitoring Initiative assessed the methamphetamine drug threat in New...

read more

Developing Novel Therapeutics for Addiction

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders.  Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS.  IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT).  We are also developing a novel vaccine (IXT-v100) against methamphetamine.